Abstract | AIM: PATIENTS AND METHODS: RESULTS: Out of 79 patients, 33 (41.8%) achieved quasipathological complete responses (QpCR). Univariate analysis associated negative ER (p<0.001), negative PR (p=0.007), triple-negative subtype (TNBC; p=0.001), high Ki-67 (p=0.022) and low class III β tubulin (p=0.032) with QpCR. Multivariate analyses associated only negative ER (p=0.050) and low class III β tubulin (p=0.028) and only non-basal subtype in TNBC with QpCR. CONCLUSION: NAC-TC may be especially effective in ER- breast cancer with low class III β tubulin or non-basal TNBC.
|
Authors | Kazuhiro Shimada, Takashi Ishikawa, Kumiko Kita, Kazutaka Narui, Sadayoshi Sugae, Daisuke Shimizu, Mikiko Tanabe, Takeshi Sasaki, Takashi Chishima, Yasushi Ichikawa, Itaru Endo |
Journal | Anticancer research
(Anticancer Res)
Vol. 35
Issue 2
Pg. 907-12
(Feb 2015)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 25667473
(Publication Type: Journal Article)
|
Copyright | Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. |
Chemical References |
- Biomarkers, Tumor
- Taxoids
- Tubulin
- Docetaxel
- Cyclophosphamide
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Tumor
(metabolism)
- Chemotherapy, Adjuvant
- Cyclophosphamide
(administration & dosage)
- Docetaxel
- Female
- Humans
- Middle Aged
- Taxoids
(administration & dosage)
- Triple Negative Breast Neoplasms
(drug therapy, metabolism)
- Tubulin
(metabolism)
|